Isaderm 5 mg/g + 1 mg/g Gel for Dogs

Composition

Each g contains:

Active substances:

Fusidic acid 5 mg

Betamethasone (as betamethasone valerate) 1 mg

Excipients:

White to off-white, opaque gel.

3

Pharmacological properties

4.1 ATCvet code: QD07 CC01

4.2 Pharmacodynamics

Betamethasone valerate is a potent corticosteroid that possesses anti-inflammatory and anti-pruritic properties.

Fusidic acid has a steroidal structure but does not possess any steroid-like effects. It belongs to the class of antibiotics called Fusidanes. Fusidic acid acts by prohibiting the protein synthesis of bacteria when it binds to elongation factor G (required for translocation on the bacterial ribosome after peptide bond formation during protein synthesis).

Its action is largely bacteriostatic, but at high concentrations (2 to 32-fold higher than the MIC) the effect may be bactericidal. Fusidic acid has activity against Gram-positive bacteria, namely Staphylococcus spp. (particularly S.pseudintermedius) including penicillinase producing species. It is also active against streptococci.

Data based on studies conducted mainly in Europe but also in North America between 2002 and 2011.

Two major mechanisms of resistance to fusidic acid have been reported in S. aureus – the alteration of the drug target site which is due to chromosomal mutations in FusA (encoding elongation factor EF-G) or FusE encoding ribosome protein L6, and the protection of the drug target site by FusB family proteins, including fusB, fusC, and fusD. The fusB determinant originally was found on the plasmid in S. aureus but has also been found on a transposon-like element or in a staphylococcal pathogenicity. No cross-resistance between fusidic acid and other antibiotics that are in clinical use has been identified.

4.3 Pharmacokinetics

In vitro data obtained from a study on dog skin indicates that 17 % of the applied dose of betamethasone and 2.5 % of the applied dose of fusidic acid are absorbed over 48 hours after the administration of the product to the skin. Absorption after administration to inflamed skin is likely to be greater.

3

Target species

Dogs.

3

Indications

For the topical treatment of surface pyoderma in the dog such as acute moist dermatitis (‘hot spots’) and intertrigo (skin fold dermatitis).

3

Dosage

Cutaneous use.

First, the hairs covering the lesions should be gently clipped. The affected area should then be thoroughly cleaned with an antiseptic wash before application of the gel. The amount applied should cover the affected area in a thin layer. Apply approximately 0.5 cm length of gel per 8 cm2 of lesion, twice daily, for a minimum period of 5 days. Treatment should continue for 48 hours after the lesion has resolved. The treatment period should not exceed 7 days. If there is no response within three days, or the condition deteriorates, the diagnosis should be re-evaluated.

3

Contraindications

Do not use in cases of known hypersensitivity to the active substances or to any of the excipients.

Do not use for the treatment of deep pyoderma.

Do not use in pyotraumatic furunculosis and pyotraumatic folliculitis with ‘satellite’ lesions of papules or pustules.

Do not use where fungal or viral infection is present.

Do not apply to the eye.

Do not use over large surface areas or for prolonged treatment.

See section 3.7.

3

Adverse reactions

Dogs:

Very rare (<1 animal / 10,000 animals treated, including isolated reports): Systemic disorder1 (e.g. Skin thinning, Delayed healing, Adrenal gland disorder2); Hypersensitivity reaction3; Application site pigmentation disorder4.

1 May be triggered by prolonged and intensive use of topical corticosteroid preparations or treatment of a large cutaneous surface (>10%).

2 Suppression of adrenal function.

3 Discontinue use if develops.

4 Depigmentation of the skin.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3

Warnings

Special precautions for safe use in the target species:

Official, national and regional antimicrobial policies should be taken into account when the product is used.

Betamethasone valerate can be absorbed percutaneously and may cause temporary suppression of adrenal function.

The dog should be prevented from licking treated lesions and so ingesting the product. Where there is a risk of self-trauma or a risk of accidental transfer to the eye, for example, application of the product on the forelimb, preventative measures such as the use of an Elizabethan collar should be considered.

Pyoderma is often secondary in nature. The underlying cause should be identified and treated.

It is recommended that use of the product should be based on bacteriological sampling and susceptibility testing. If this is not possible, therapy should be based on epidemiological information about susceptibility of the target bacteria. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to fusidic acid.

The safety of the combination has not been assessed in puppies of less than 7 months.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Corticosteroids may produce irreversible effects in the skin; they can be absorbed and may have harmful effects, especially with frequent and extensive contact or in pregnancy. Pregnant women should take special care to avoid accidental exposure. Personal protective equipment consisting of single-use disposable gloves should be worn when handling the veterinary medicinal product.

Wash hands after having applied the product.

Care should be taken to avoid accidental ingestion by a child. In the case of accidental ingestion, seek medical advice immediately and show the package leaflet to the physician.

People with known hypersensitivity to the active ingredients or to any of the excipients should avoid contact with the veterinary medicinal product.

Special precautions for the protection of the environment:

Not applicable.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable

3

Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established during pregnancy and lactation.

Pregnancy and lactation:

Laboratory studies showed that topical application of betamethasone in pregnant females may lead to malformations in neonates. The use of the product is not recommended during pregnancy and lactation.

3

Interactions

None known.

3

Overdose

For possible signs see 3.6 above.

3

Special warnings

None.

3

Withdrawal period

Not applicable.

3

Incompatibilities

None known.

3

Immediate packaging

Internally lacquered aluminium tube closed with a white HDPE screw cap.

Pack sizes:

Cardboard box with 1 x 15 g

Cardboard box with 1 x 30 g

Not all pack sizes may be marketed.

3

Storage

Do not store above 30 °C.

Do not refrigerate or freeze.

Keep the tube in the outer carton.

3

Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

Shelf life after first opening the immediate packaging: 6 weeks.

3

Disposal of unused product

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

3

Additional information

Vm 24883/5000

8 DATE OF FIRST AUTHORISATION

27 March 2014

9 DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

September 2026

10 CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT

Veterinary medicinal product subject to prescription.

Find more product information by searching for the ‘Product Information Database’ on www.gov.uk.

Approved: 15 April 2026

3

Registration holder

Dechra Veterinary Products A/S

3